You are here

Home › Listings › Life Sciences › XORTX Therapeutics Inc.

XORTX Therapeutics Inc.

XORTX Therapeutics Inc.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
XRX
CSE Index: 
Currency: 

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.  Additional information on XORTX Therapeutics is available at www.xortx.com.

You are here

Home

XORTX Therapeutics Inc. (XRX)

SEDAR Information

Search form

Company Info

Address
4000, 421 – 7th Avenue SW
Calgary, AB T2P 4K9
Canada
Phone
(403) 455 7717
Email
adavidoff@xortx.com
Website
http://xortx.com
Listing date
Wednesday, September 30, 2015
Transfer Agent
TSX Trust Company
Auditor
Smythe LLP

Advertisement

Publicité

Capitalization

Issued & Outstanding: 
9,728,687
Reserved for Issuance: 
2,362,168
Total equity shares, as if converted: 
12,090,855

Company Officers

Allen Davidoff, President and Chief Executive Officer
Charlotte May, Corporate Secretary
W. Bruce Rowlands, Chairman
Paul J. Van Damme, Director
Ian Klassen, Director
Jacqueline Le Saux, Director
William Farley, Director
Amar Keshri, Chief Financial Officer
Dr. Stephen Haworth, Chief Medical Officer

News Releases

15/10/2021

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

15/10/2021

XORTX Announces Results from Mount Sinai’s COVID-19 Clinical Study ● Early, High Uric Acid is Independently Associated with Acute Kidney Injury and Mortality in COVID-19 ●

Bulletins

21/09/2021

2021-0926 – Consolidation - XORTX Therapeutics Inc. (XRX)

Le 21 septembre/September 2021

XORTX Therapeutics Inc. has announced a consolidation of its issued and outstanding common shares on the basis of 1 post-consolidation common share for every 11.74 pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 9,443,508 common shares.

The name and symbol will not change.

CSE Filings

Form 6 - Certificate of Compliance

Form 9 - Notice of Issuance of Securities

CDS Confirmation

TSX Trust Confirmation

Specimen Certificate

Advertisement

Publicité

Latest CSE News